78. Aerobactin Gene iuc as a Virulence Marker Associated with Increased Mortality in Carbapenem-Resistant Klebsiella pneumoniae infections: A Multicenter Observational Cohort Study from China
Rattachement africain : us, cn. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Abstract Background Despite growing reports of virulence gene acquisition in carbapenem-resistant Klebsiella pneumoniae (CRKP) strains, the clinical implications of these infections remain poorly understood. Methods In this study, 246 hospitalized patients with clinical CRKP infections were enrolled from six hospitals across China between 2017 and 2019 (CRACKLE-2 China Cohort). All CRKP isolates underwent whole-genome sequencing to determine sequence types and the presence of virulence genes, including iuc (aerobactin), iro (salmochelin), and mucoid phenotype regulators (rmpADC and rmpA2). Clinical, microbiological, and outcome data were compared by iuc status, and multivariable logistic regression was used to assess factors associated with 30-day mortality. Kaplan-Meier analysis was performed to evaluate 30-day survival. Results Among the 246 CRKP isolates, ST11 (78%, 192/246) and ST15 (14%, 34/246) were predominant. iuc was detected in 63% (154/246) of the isolates. rmpA2 (Pearson coefficient r=0.9; P< 0.01) and rmpA (r=0.7; P< 0.01) were highly correlated with iuc. In only 6/246 isolates (2%) iro was detected, five of which were iuc-positive. Demographics and clinical characteristics did not differ between patients infected with iuc-positive and iuc-negative isolates (Table 1). Clinical outcomes were worse in iuc-positive CRKP infections; unadjusted 30-day mortality was higher in the iuc-positive group compared to the iuc-negative group (16% vs. 5%, 24/154 vs. 5/92; P< 0.05). Additionally, the 30-day DOOR outcomes were significantly different, and the presence of iuc was associated with less desirable outcomes (DOOR probability 37.8%; 95% Halperin confidence interval: 31.3%-44.7%, Table 2). After adjusting for potential confounders, iuc-positive CRKP infections remained independently predictive of increased 30-day all-cause mortality (adjusted odds ratio [aOR], 4.10; 95% CI, 1.31-12.86; P=0.016) (Table 3). Kaplan-Meier survival analysis further demonstrated significantly poorer survival among patients with iuc-positive infections (log-rank p=0.018) (Figure 1). Conclusion These findings suggest that the presence of iuc contributes to increased mortality in CRKP infections and highlight the need for its surveillance in clinical settings. Disclosures Angelique E. Boutzoukas, MD, MPH, Elion Therapeutics: Advisor/Consultant|Entasis Therapeutics Inc., an affiliate of Innoviva Specialty Therapeutics, Inc.: Board Member David van Duin, MD, PhD, AbbVie Inc: Advisor/Consultant|Merck & Co., Inc.: Advisor/Consultant|Merck & Co., Inc.: Grant/Research Support|Parexel International: DSMB|Pfizer, Inc.: Advisor/Consultant|Pfizer, Inc.: Honoraria|Roche Pharmaceuticals: Advisor/Consultant|TEVA: Advisor/Consultant
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- 78. Aerobactin Gene iuc as a Virulence Marker Associated with Increased Mortality in Carbapenem-Resistant Klebsiella pneumoniae infections: A Multicenter Observational Cohort Study from China
- Date Crossref
- 01/01/2026
- Éditeur
- Oxford University Press (OUP)
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Center for Discovery pays non établi dans la noticeÉtablissement de santé
-
George Washington University pays non établi dans la noticeUniversité ou école supérieure
-
Duke Energy (United States) pays non établi dans la noticeEntreprise
-
Clinical Research Institute pays non établi dans la noticeStructure de recherche
-
Duke Raleigh Hospital pays non établi dans la noticeÉtablissement de santé
-
Sir Run Run Shaw Hospital pays non établi dans la noticeÉtablissement de santé
-
First Affiliated Hospital Zhejiang University pays non établi dans la noticeÉtablissement de santé
-
Zhejiang University State Key Laboratory for Diagnosis and Treatment of Infectious Diseases pays non établi dans la noticeUniversité ou école supérieure
-
Chinese Academy of Medical Sciences & Peking Union Medical College pays non établi dans la noticeUniversité ou école supérieure
-
Peking Union Medical College Hospital Department of Internal Medicine pays non établi dans la noticeÉtablissement de santé
-
Duke Medical Center pays non établi dans la noticeÉtablissement de santé
-
University at Buffalo pays non établi dans la noticeUniversité ou école supérieure
Center for Discovery, George Washington University et Duke Energy (United States), avec 9 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.